Catalyst Wire Dossier Catalyst Wire Dossier

Apalutamide (Erleada)

apalutamide · Janssen Biotech, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Apalutamide (Erleada), covering 2021-08-16 to 2021-08-16. Get the full timeline:

Most recent: Clinical Trial Update: An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) [Phase 3]

See pricing